Ofri Mosenzon

发表

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.

T. Pieber, C. Mathieu, B. Bode, 2021, The lancet. Diabetes & endocrinology.

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

T. Wadden, S. Calanna, M. Thomsen, 2021, Diabetes, obesity & metabolism.

Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach

Ofri Mosenzon, Meir Schechter, Matan Fischer, 2022, Diabetes, obesity & metabolism.

The effect of lifestyle intervention on cardiometabolic risk factors in mental health rehabilitation hostel residents at-risk: a cluster-randomized controlled 15-month trial

R. Goldsmith, R. Endevelt, Ofri Mosenzon, 2022, International Journal of Obesity.

Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults

Lawrence A Leiter, S. Verma, G. Chodick, 2022, Cardiovascular Diabetology.

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

F. Greenway, T. Wadden, J. Rosenstock, 2021, JAMA.

Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i

L. Blonde, Ofri Mosenzon, Chethana Ramesh, 2021, Diabetes, obesity & metabolism.

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

J. Rosenstock, P. Weimers, Ofri Mosenzon, 2022, Cardiovascular Diabetology.

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs

S. Hadjadj, Ofri Mosenzon, D. Cherney, 2022, Kidney international reports.

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Deepak L. Bhatt, M. Sabatine, S. Murphy, 2021, Diabetes Care.

Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial.

Lawrence A Leiter, E. Braunwald, B. Scirica, 2021, Journal of the American College of Cardiology.

Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58

Deepak L. Bhatt, Lawrence A Leiter, A. Parkhomenko, 2020 .

What is important for people with type 2 diabetes? A focus group study to identify relevant aspects for Patient-Reported Outcome Measures in diabetes care

R. Calderon-Margalit, O. Manor, Ofri Mosenzon, 2022, PloS one.

Spontaneous tumor lysis syndrome in solid tumors: really a rare condition?

Ofri Mosenzon, A. Braester, Y. Horn, 2003, The American journal of the medical sciences.

Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study

N. Vaisman, Ofri Mosenzon, B. Hirshberg, 2022, Clinical kidney journal.

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)

T. Wadden, R. Kushner, W. Garvey, 2021, Journal of the Endocrine Society.

Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo.

S. Hadjadj, K. Tuttle, Ofri Mosenzon, 2023, Kidney international.

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

Lawrence A Leiter, M. Sabatine, D. McGuire, 2021, JAMA cardiology.

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

I. Lingvay, S. Wharton, D. Dicker, 2021, Postgraduate medicine.

Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study

F. Visseren, Ofri Mosenzon, J. Westerink, 2022, Diabetes, obesity & metabolism.

Diabetes and Stroke: What Are the Connections?

S. Sacco, A. Rabinstein, A. Cheng, 2023, Journal of stroke.

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

I. Lingvay, Ofri Mosenzon, Hiren Patel, 2023, Cardiovascular Diabetology.

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition

E. Gottlieb, E. Bernal-Mizrachi, E. Cerasi, 2023, JCI insight.

Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses

Matthew J. Crowley, K. Khunti, J. Buse, 2021, Diabetes Therapy.

Abstract #1003901: Once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History

T. Wadden, R. Kushner, W. Garvey, 2021 .

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)

T. Wadden, R. Kushner, W. Garvey, 2021, Journal of the Endocrine Society.

The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study

G. Filippatos, L. Ruilope, G. Bakris, 2023, Diabetes, obesity & metabolism.

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence

A. Karasik, Ofri Mosenzon, Meir Schechter, 2023, Cardiovascular Diabetology.

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.

J. Rosenstock, S. Bain, R. Trevisan, 2023, New England Journal of Medicine.

Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data

A. Karasik, Ofri Mosenzon, Meir Schechter, 2023, Diabetes, obesity & metabolism.

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

E. Braunwald, B. Scirica, R. Frederich, 2014, Circulation.